Clin2
NCT07646587Possibly a fitRecruiting

Safety Study of WIN378 for Moderate-Severe COPD

COPD (Chronic Obstructive Pulmonary Disease)

Part of Lungs & breathing clinical trials.

This study tests a new drug called WIN378 in people with moderate-to-severe COPD (chronic lung disease). It will check if the drug is safe and how the body processes it, which may help improve breathing and reduce flare-ups.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
105 people
Ages
40 years to 80 years
Study type
Interventional

Who can take part

  • Be between 40 and 80 years old
  • Have moderate-to-severe COPD confirmed by breathing tests (FEV1 between 30–80% of predicted normal)
  • Be on stable triple inhaled therapy (three COPD inhalers) for at least 3 months with no recent changes
  • Have smoked at least 10 pack-years in the past but quit at least 6 months ago
  • Have higher-than-normal eosinophil counts (a type of white blood cell)
  • Have a stable weight and BMI in an acceptable range

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07351734Recruiting· Phase 2
Testing JKN2403 for COPD: a new treatment option

This study tests an experimental drug called JKN2403 for people with moderate to severe COPD. It aims to see if the drug can reduce flare-ups and improve breathing compared to a placebo (a dummy pill).

Guangzhou, Guangdong
NCT07658339Not yet recruiting· Phase 3
Testing an inhaled drug for COPD symptoms

This trial tests a new inhaled drug, HSK39004, to see if it safely improves breathing and quality of life in people with moderate to severe COPD. You may join if you are between 40 and 80, have a COPD diagnosis with certain lung function results, and have at least some shortness of breath with daily activities.

Beijing
NCT07076290Not yet recruiting· Phase 1
Study of R-3750 for mild to moderate COPD

This trial tests an investigational drug called R-3750 in patients with mild to moderate COPD. It aims to see if the drug is safe and helps control symptoms. Eligible patients must have had COPD for at least a year, have mild to moderate airflow limitation, and have had at least one COPD flare-up in the past year.

NCT07780669Not yet recruiting· Phase 3
Study of a new drug for moderate to severe COPD in smokers

This study tests a new medication (GSK5784283) for people with moderate to severe COPD who have a certain type of inflammation (eosinophilic). Participants must be on standard inhaler therapy and have a history of smoking. The trial will compare the new drug to a placebo.

NCT07363694Recruiting· Phase 2/Phase 3
Study of PF-07275315 for moderate to severe COPD

This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.

Birmingham, Alabama
NCT07082738Recruiting· Phase 2
Study of AZD6793 for people with moderate to very severe COPD

This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.

Birmingham, Alabama

Hear when a new COPD (Chronic Obstructive Pulmonary Disease) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.